Collateral Genomic Deletions as Targetable Vulnerabilities in Cancer
RP140612 DePinho (PI) 03/01/15 – 02/28/18
Cancer Prevention and Research Institute – IIRA
Major Goal is to profile the biochemical consequences of ENO2 shRNA knockdown in ENO1 null and ENO1 rescued glioma cells in vitro and in vivo and to identify and validate additional examples of collateral lethality.
In Vivo Molecular Breast Imaging with TC 99M Sestamibi for the Prediction of Multidrug Resistance in Triple Negative Breast Cancers
CABI/GE In-Kind Research Grant Rauch (PI) 09/01/15 – 08/31/18
Multi-Investigator Imaging (MI2) Research Award
Major Goal is to test the ability of a new imaging modality of Molecular Breast Imaging (MBI) to predict early treatment response to chemotherapy in triple negative breast cancer.
Role: Co-Principal Investigator
Passenger Deletion of ENO1 as a Targetable Vulnerability in Cancer
RSG-15-145-01- CDD Muller (PI) 01/01/16 – 12/31/19
American Cancer Society Research Scholar Award
Major Goal is to utilize pro-drug moieties from clinically successful anti-viral phosphonate nucleotide analogues to improve the cell permeability of inhibitors of the glycolytic enzyme Enolase.
Role: Principal Investigator